NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma ...
Finanznachrichten2d
NuCana plc: NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Mr. Griffith continued, "Turning to NUC-3373, our second anti-cancer program is a targeted thymidylate synthase inhibitor with immune modulating properties. It is currently being evaluated in a ...
Medscape5d
The Concurrent Chemoradiation Paradigm-General Principles
Summary and Introduction Clinical Application—Disease Entities Theoretical Framework for Therapy−The 'Steel Paradigm' Conclusion References Theoretical Framework for Therapy−The 'Steel ...
SciELO5d
Evaluation of homocysteine, folate, vitamin B12, and vitamin D levels in pregnant women with recurrent vaginitis
OBJECTIVE: The aim of this study was to evaluate the levels of homocysteine, vitamin B12, folic acid, and vitamin D in pregnant women with recurrent vaginitis and determine whether these parameters ...